By Dr Mark Alastair Boyd

Journal articles

Haskelberg H; Mallon PWG; Hoy J; Amin J; Moore C; Phanuphak P; Ferret S; Belloso WH; Boyd MA; Cooper DA; Emery S; Cooper D, 2014, 'Bone mineral density over 96 weeks in adults failing first-line therapy randomised to raltegravir/lopinavir/ritonavir compared to standard second-line therapy', Journal of Acquired Immune Deficiency Syndromes, http://dx.doi.org/10.1097/QAI.0000000000000288

Achhra AC; Boyd MA; Law MG; Matthews GV; Kelleher AD; Cooper DA; Han A, 2014, 'Moving away from ritonavir, abacavir, tenofovir, and efavirenz (RATE) - Agents that concern prescribers and patients: A feasibility study and call for a trial', PLoS ONE, 9, pp. e99530, http://dx.doi.org/10.1371/journal.pone.0099530

Wright ST; Hoy J; Mulhall B; OʼConnor CC; Petoumenos K; Read T; Smith D; Woolley I; Boyd MA; O'Connor C, 2014, 'Determinants of Viremia Copy-Years in People With HIV/AIDS After Initiation of Antiretroviral Therapy', JAIDS Journal of Acquired Immune Deficiency Syndromes, 66, pp. 55 - 64, http://dx.doi.org/10.1097/qai.0000000000000125

Haskelberg H; Pocock N; Amin J; Ebeling PR; Emery S; Carr A; Post J; Medland N; Boyd M, 2014, 'Hip structural parameters over 96 weeks in HIV-infected adults switching treatment to tenofovir-emtricitabine or abacavir-lamivudine', PLoS ONE, 9, pp. e94858, http://dx.doi.org/10.1371/journal.pone.0094858

Revell AD; Boyd MA; Wang D; Emery S; Gazzard B; Reiss P; van Sighem A; Montaner JS; Lane HC; Larder BA, 2014, 'A comparison of computational models with and without genotyping for prediction of response to second-line HIV therapy', HIV Medicine, 15, pp. 442 - 448, http://dx.doi.org/10.1111/hiv.12156

Haskelberg H; Mallon PWG; Hoy J; Amin J; Moore C; Phanuphak P; Ferret S; Belloso WH; Boyd MA; Cooper DA; Emery S, 2014, 'Bone mineral density over 96 weeks in adults failing first-line therapy randomized to raltegravir/lopinavir/ ritonavir compared with standard second-line therapy', Journal of Acquired Immune Deficiency Syndromes, 67, pp. 161 - 168, http://dx.doi.org/10.1097/QAI.0000000000000288

Achhra AC; Boyd MA, 2013, 'Antiretroviral regimens sparing agents from the nucleoside(tide) reverse transcriptase inhibitor class: A review of the recent literature', AIDS Research and Therapy, 10, http://dx.doi.org/10.1186/1742-6405-10-33

Boyd MA; Cooper DA, 2013, 'SPRING-2 the future of antiretroviral therapy', The Lancet Infectious Diseases, 13, pp. 908 - 909, http://dx.doi.org/10.1016/S1473-3099(13)70194-4

Martin A; Moore C; Mallon PWG; Hoy J; Emery S; Belloso W; Phanuphak P; Ferret S; Cooper DA; Boyd MA, 2013, 'Bone mineral density in HIV participants randomized to raltegravir and lopinavir/ritonavir compared with standard second line therapy', AIDS, 27, pp. 2403 - 2411, http://dx.doi.org/10.1097/01.aids.0000432534.47217.b4

Byakwaga H; Petoumenos K; Ananworanich J; Zhang F; Boyd MA; Sirisanthana T; Li PCK; Lee C; Mean CV; Saphonn V; Omar SFS; Pujari S; Phanuphak P; Lim PL; Kumarasamy N; Chen YMA; Merati TP; Sungkanuparph S; Ditangco R; Oka S; Tau G; Zhou J; Law MG; Emery S; Han A, 2013, 'Predictors of clinical progression in HIV-1-infected adults initiating combination antiretroviral therapy with advanced disease in the Asia-Pacific region: Results from the TREAT Asia HIV Observational Database', Journal of the International Association of Providers of AIDS Care, 12, pp. 270 - 277, http://dx.doi.org/10.1177/1545109712469684

Wright S; Boyd MA; Yunihastuti E; Law M; Sirisanthana T; Hoy J; Pujari S; Lee MP; Petoumenos K; Templeton D; Han A, 2013, 'Rates and Factors Associated with Major Modifications to First-Line Combination Antiretroviral Therapy: Results from the Asia-Pacific Region', PLoS ONE, 8, pp. e64902, http://dx.doi.org/10.1371/journal.pone.0064902

Jansson J; Wilson DP; Carr A; Petoumenos K; Boyd MA, 2013, 'Currently available medications in resource-rich settings may not be sufficient for lifelong treatment of HIV', AIDS, 27, pp. 1245 - 1251, http://dx.doi.org/10.1097/QAD.0b013e32835e163d

Boyd MA; Donovan B, 2013, 'Antiretroviral therapy: Dolutegravir sets SAIL(ING)', The Lancet, 382, pp. 664 - 666, http://dx.doi.org/10.1016/S0140-6736(13)61456-7

Martin A; Moore CL; Mallon PWG; Hoy JF; Emery S; Belloso WH; Phanuphak P; Ferret S; Cooper DA; Boyd MA; Second-Line Study Team , 2013, 'HIV lipodystrophy in participants randomised to lopinavir/ritonavir (LPV/r) +2-3 nucleoside/nucleotide reverse transcriptase inhibitors (N(t)RTI) or LPV/r + raltegravir as second-line antiretroviral therapy.', PloS one, 8, http://dx.doi.org/10.1371/journal.pone.0077138

Suzuki K; Hattori S; Marks K; Ahlenstiel C; Maeda Y; Ishida T; Millington M; Boyd M; Symonds G; Cooper DA; Okada S; Kelleher AD, 2013, 'Promoter Targeting shRNA Suppresses HIV-1 Infection In vivo Through Transcriptional Gene Silencing', Molecular Therapy Nucleic Acids, 2, pp. e137, http://dx.doi.org/10.1038/mtna.2013.64

Wright ST; Petoumenos K; Boyd MA; Carr AD; Downing S; O''connor C; Grotowski M; Law MG, 2013, 'Ageing and long-term CD4 cell count trends in HIV-positive patients with 5 years or more combination antiretroviral therapy experience', HIV Medicine, 14, pp. 208 - 216, http://dx.doi.org/10.1111/j.1468-1293.2012.01053.x

Boyd MA, 2013, 'Ritonavir-boosted lopinavir plus nucleoside or nucleotide reverse transcriptase inhibitors versus ritonavir-boosted lopinavir plus raltegravir for treatment of HIV-1 infection in adults with virological failure of a standard first-line ART regimen (SECOND-LINE): A randomised, open-label, non-inferiority study', Lancet, 381, pp. 2091 - 2099, http://dx.doi.org/10.1016/S0140-6736(13)61164-2

Schneider K; Nwizu CA; Kaplan R; Anderson JS; Wilson DP; Emery S; Cooper DA; Boyd MA, 2013, 'The Potential Cost and Benefits of Raltegravir in Simplified Second-Line Therapy among HIV Infected Patients in Nigeria and South Africa', PLoS ONE, 8, pp. e54435, http://dx.doi.org/10.1371/journal.pone.0054435

Jansson J; Wilson D; Carr A; Petoumenos K; Boyd M, 2012, 'Currently available medications may not be sufficient for lifelong treatment of HIV', JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 15, pp. 4 - 4, http://dx.doi.org/10.7448/IAS.15.6.18077

Carey DL; Pett SL; Bloch M; Wand H; MacRae K; Beileiter K; Ray J; Boyd MA; Emery S; Cooper DA, 2012, 'A randomized study of pharmacokinetics, efficacy, and safety of 2 raltegravir plus atazanavir strategies in ART-treated adults', JAIDS: Journal of Acquired Immune Deficiency Syndromes, 60, pp. 143 - 149, http://dx.doi.org/10.1097/QAI.0b013e318252f97e

Haskelberg H; Hoy J; Amin J; Ebeling PR; Emery S; Carr AD, 2012, 'Changes in Bone Turnover and Bone Loss in HIV-Infected Patients Changing Treatment to Tenofovir-Emtricitabine or Abacavir-Lamivudine', PLoS ONE, 7, pp. e38377, http://dx.doi.org/10.1371/journal.pone.0038377

Boyd MA, 2012, 'Dolutegravir — a promising antiretroviral in development', Lancet Infectious Diseases, 12, pp. 90 - 91, http://dx.doi.org/10.1016/S1473-3099(11)70291-2

McManus H; O'Connor CC; Boyd MA; Broom J; Russell D; Watson K; Roth N; Read PJ; Law M; Petoumenos K; Templeton D; Han A, 2012, 'Long-term survival in HIV positive patients with up to 15 years of antiretroviral therapy', PLoS One, 7, pp. Article numbere48839, http://dx.doi.org/10.1371/journal.pone.0048839

Boyd MA; Cooper DA, 2012, 'Optimisation of HIV care and service delivery: doing more with less', Lancet, 380, pp. 1860 - 1866, http://dx.doi.org/10.1016/S0140-6736(12)61154-4

Avihingsanon A; van der Lugt J; Singphore U; Gorowara M; Boyd MA; Ananworanich J; Phanuphak P; Burger DM; Ruxrungtham K, 2012, 'Pharmacokinetics and 48 week efficacy of adjusted dose indinavir/ritonavir in rifampicin-treated HIV/tuberculosis-coinfected patients: A pilot study', AIDS Research and Human Retroviruses, 28, pp. 1170 - 1176, http://dx.doi.org/10.1089/aid.2011.0247

Boyd MA; Mohapi L, 2012, 'STRETCHing delivery of HIV health services', Lancet, 380, pp. 865 - 867, http://dx.doi.org/10.1016/S0140-6736(12)60952-0

Byakwaga H; Purcell DJ; French MA; Amin J; Lewin S; Haskelberg H; Kelleher AD; Garsia RJ; Boyd MA; Cooper DA; Emery S, 2011, 'Intensification of antiretroviral therapy with raltegravir or addition of hyperimmune bovine colostrum in HIV-infected patients with suboptimal CD4 + T-cell response: A randomized controlled trial', Journal of Infectious Diseases, 204, pp. 1532 - 1540, http://jid.oxfordjournals.org/content/204/10/1532

Wilson DP; Grulich AE; Boyd MA, 2011, 'Overly optimistic forecasts of the impact of treatment as HIV prevention for men who have sex with men', Clinical Infectious Diseases, 53, pp. 611 - 612

Revell ; Wang ; Boyd MA; Emery S; Pozniak A; de WF; Harrigan R; Montaner JSG; Lane C; Larder B, 2011, 'The development of an expert system to predict virological response to HIV therapy as part of an online treatment support tool', AIDS, 25, pp. 1855 - 1863, http://dx.doi.org/10.1097/QAD.0b013e328349a9c2

Boyd MA; Hill AM, 2010, 'Clinical management of treatment-experienced, HIV/AIDS patients in the combination antiretroviral therapy era', PharmacoEconomics, 28, pp. 17 - 34, http://dx.doi.org/10.2165/11587420-000000000-00000

Boyd MA; Nwizu CA, 2010, 'Operational research in HIV priority areas: the African way', The Lancet, 376, pp. 4 - 6, http://dx.doi.org/10.1016/S0140-6736(10)60972-5

Boyd MA; Hill A, 2010, 'Clinical management of treatment-experienced, HIV/AIDS patients in the combination antiretroviral therapy era', Pharmacoeconomics, 28, pp. 17 - 34

Boyd MA, 2010, 'Current and future management of treatment failure in low- and middle-income countries', Current opinion in HIV & AIDS, 5, pp. 83 - 89

Zhou J; Li PCK; Kumarasamy N; Boyd MA; Chen YMA; Sirisanthana T; Sungkanuparph S; Oka S; Tau G; Phanuphak P; Saphonn V; Zhang FJ; Omar SFS; Lee CKC; Ditangco R; Merati TP; Lim PL; Choi JY; Law MG; Pujari S, 2010, 'Deferred modification of antiretroviral regimen following documented treatment failure in Asia: results from the TREAT Asia HIV Observational Database (TAHOD)', HIV Medicine, 11, pp. 31 - 39

Carey DL; Amin J; Boyd MA; Petoumenos K; Emery S, 2010, 'Lipid profiles in HIV-infected adults receiving atazanavir and atazanavir/ritonavir: systematic review and meta-analysis of randomised controlled trials', Journal of Antimicrobial Chemotherapy, 65, pp. 1878 - 1888

Boyd MA, 2009, 'Improvements in antiretroviral therapy outcomes over calendar time', Current Opinion in HIV and AIDS, 4, pp. 194 - 199, http://dx.doi.org/10.1097/COH.0b013e328329fc8d

Boyd M, 2009, 'Clinical research in low- And middle-income countries', Virtual Mentor, 11, pp. 511 - 515, http://dx.doi.org/10.1001/virtualmentor.2009.11.7.jdsc1-0907

Boyd MA; Emery S; Cooper DA, 2009, 'Antiretroviral roll-out: the problem of second-line therapy', Lancet, 374, pp. 185 - 186

Mcintyre GJ; Yu Y; Tran A; Jaramillo AB; Arndt AJ; Millington ML; Boyd MP; Elliott FA; Shen SW; Murray JM; Applegate TL, 2009, 'Cassette deletion in multiple shRNA lentiviral vectors for HIV-1 and its impact on treatment success', Virology Journal, 6, pp. 184, http://www.virologyj.com/content/6/1/184

Byakwaga H; Zhou J; Petoumenos K; Law MG; Boyd MA; Emery S; Cooper DA; Mallon PW, 2009, 'Effect of nucleoside reverse transcriptase inhibitors on CD4 T-cell recovery in HIV-1-infected individuals receiving long-term fully suppressive combination antiretroviral therapy', HIV Medicine, 10, pp. 143 - 151

Byakwaga H; Murray JM; Petoumenos K; Kelleher AD; Law MG; Boyd MA; Emery S; Mallon PW; Cooper DA, 2009, 'Evolution of CD4+T cell count in HIV-1-infected adults receiving antiretroviral therapy with sustained long-term virological suppression', AIDS Research and Human Retroviruses, 25, pp. 569 - 576

Boyd MA, 2009, 'Improvements in antiretroviral therapy outcomes over calendar time', Current opinion in HIV & AIDS, 4, pp. 194 - 199, http://dx.doi.org/10.1097/COH.013e328329fc8d

Colebunders R; French M; Oelrichs R; Boyd M, 2008, 'Editorial introductions', Current Opinion in HIV and AIDS, 3, http://dx.doi.org/10.1097/COH.0b013e32830890a4

Oelrichs R; Boyd M, 2008, 'Evidence and policy in the globalized response to AIDS', Current Opinion in HIV and AIDS, 3, pp. 477 - 480, http://dx.doi.org/10.1097/COH.0b013e328303ba0b

Boyd MA; Truman M; Holes G; Anderson JA; Dwyer DE; Carr AD, 2008, 'A randomized study to evaluate injection site reactions using three different enfuvirtide delivery mechanisms (the OPTIONS study)', Antiviral Therapy, 13, pp. 449 - 453

Boyd MA; Byakwaga H, 2008, 'Considering the benefits of disease-specific interventions on overall public health', Lancet Infectious Diseases, 8, pp. 278 - 278

Boyd MA; Pett SL, 2008, 'Experimental and clinical pharmacology - HIV fusion inhibitors: a review', Australian Prescriber, 31, pp. 66 - 69

Mackowiak PA; Boyd MA; Menon P; Graves S; Gordon DL, 2007, 'A Febrile Illness with Generalized Papular Rash Involving the Palms and Soles', Clinical Infectious Diseases, 44, pp. 755 - 756, http://dx.doi.org/10.1086/511651

Boyd MA; Menon P; Graves S; Gordon DL, 2007, 'A febrile illness with generalized papular rash involving the palms and soles', Clinical Infectious Diseases, 44, http://dx.doi.org/10.1086/511637

Boyd MA; Hedger S, 2007, 'An unusual cause of severe metabolic acidosis [5]', Medical Journal of Australia, 186, pp. 158, http://dx.doi.org/10.5694/j.1326-5377.2007.tb00846.x

Back to profile page